The U.S. government on Friday released its revised guidance for its Medicare drug price negotiation program, and said it clarified how it will identify the treatments and will allow drug companies to publicly discuss the negotiation at their discretion.
Tag Archive for: CMS
UCLA researchers estimated annual spending of $2 billion for a low-end estimate of 86,000 patients receiving Leqembi, and $5.1 billion if around 216,000 eligible patients were treated with the drug.
The government will launch the negotiation process in September by naming the first drugs it plans to target. They are expected to be the 10 pharmacy-based prescription drugs it spends the most on for the year ended May 2023.
As early as 2023, pharmaceutical manufacturers and payers will have to contend with one of the more imminent potential impacts of the law: inflationary rebates for Medicare utilization.